Pfizer 4Q Revenues: $13.1 billion (-3%) 4Q Earnings: $1.2 billion (-52%) FY Revenues: $49.6 billion (-4%) FY Earnings: $9.1 billion (-58%) Comments: Global vaccine sales were up 22% in the quarter to $1.3 billion. Consumer healthcare sales were up 4% to $953 million. Global oncology sales were $609 million, up 10%. Established product sales were down 7%, due to declining Lipitor sales in developed markets, the loss of exclusivity for Celebrex and Detrol LA in the U.S., and Aricept in Canada...